{"id":"NCT02326220","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-31","primaryCompletion":"2016-01-31","completion":"2016-04-30","firstPosted":"2014-12-29","resultsPosted":"2020-05-01","lastUpdate":"2020-05-01"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heterozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["REGN727","SAR236553","PraluentÂ®"]}],"arms":[{"label":"Placebo Q2W (Double Blind Period)","type":"EXPERIMENTAL"},{"label":"Alirocumab 150 mg Q2W (Double Blind Period)","type":"EXPERIMENTAL"},{"label":"Alirocumab 150 Q2W (Open Label Treatment Period)","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with heterozygous familial hypercholesterolemia (HeFH) undergoing weekly or bi-weekly LDL apheresis therapy.","primaryOutcome":{"measure":"Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18","timeFrame":"Week 7 to Week 18 (before start of open-label treatment)","effectByArm":[{"arm":"Placebo Q2W (Double Blind Period)","deltaMin":0.806,"sd":0.191},{"arm":"Alirocumab 150 mg Q2W (Double Blind Period)","deltaMin":0.128,"sd":0.242}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States","Germany"]},"refs":{"pmids":["27572070","27206951"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":21},"commonTop":["Fatigue","Nasopharyngitis","Upper respiratory tract infection","Myalgia","Nausea"]}}